Droxidopa
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Droxidopa Product Information
Droxidopa is listed under API and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Droxidopa. The product is supplied by Clearsynth under CAT No. CS-O-30571.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Droxidopa
CAS No.
23651-95-8
CAT No.
CS-O-30571
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C9H11NO5
Molecular Weight
213.2
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Droxidopa is supplied with detailed characterization data compliant with regulatory guideline. Droxidopa can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Droxidopa.
Overview
"Droxidopa is a precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of"
Synonyms
Droxidopa
Application Notes
"Droxidopa is a precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of"
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.